These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18930377)

  • 61. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients.
    Lappin JM; Wijaya M; Watkins A; Morell R; Teasdale S; Lederman O; Rosenbaum S; Dick S; Ward P; Curtis J
    Schizophr Res; 2018 Sep; 199():367-373. PubMed ID: 29486959
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.
    Fond G; Boyer L; Favez M; Brunel L; Aouizerate B; Berna F; Capdevielle D; Chereau I; Dorey JM; Dubertret C; Dubreucq ; Faget C; Gabayet F; Laouamri H; Lancon C; Le Strat Y; Misdrahi D; Rey R; Passerieux C; Schandrin A; Schurhoff F; Tronche AM; Urbach M; Vidalhet P; Llorca PM; Pelissolo A;
    Psychopharmacology (Berl); 2016 Feb; 233(4):571-8. PubMed ID: 26630993
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The metabolic syndrome in an Italian psychiatric sample: a retrospective chart review of inpatients treated with antipsychotics.
    Santini I; Stratta P; D'Onofrio S; De Lauretis I; Santarelli V; Pacitti F; Rossi A
    Riv Psichiatr; 2016; 51(1):37-42. PubMed ID: 27030348
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.
    Vincenzi B; Greene CM; Ulloa M; Parnarouskis L; Jackson JW; Henderson DC
    J Psychiatr Pract; 2016 May; 22(3):175-82. PubMed ID: 27123797
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Glucoregulation in normal weight schizophrenia patients treated by first generation antipsychotics].
    Marić N; Doknić M; Damjanović A; Pekić S; Jasović-Gasić M; Popović V
    Srp Arh Celok Lek; 2008; 136(3-4):110-5. PubMed ID: 18720742
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome.
    Paredes RM; Quinones M; Marballi K; Gao X; Valdez C; Ahuja SS; Velligan D; Walss-Bass C
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1139-48. PubMed ID: 24565079
    [TBL] [Abstract][Full Text] [Related]  

  • 67. No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain.
    Brandl EJ; Tiwari AK; Zai CC; Chowdhury NI; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
    Psychiatry Res; 2014 Oct; 219(2):255-60. PubMed ID: 24953421
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.
    Newcomer JW; Haupt DW; Fucetola R; Melson AK; Schweiger JA; Cooper BP; Selke G
    Arch Gen Psychiatry; 2002 Apr; 59(4):337-45. PubMed ID: 11926934
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
    Jin H; Meyer JM; Mudaliar S; Jeste DV
    Schizophr Res; 2008 Mar; 100(1-3):70-85. PubMed ID: 18206351
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genetic Determinants of Clozapine-Induced Metabolic Side Effects.
    Vasudev K; Choi YH; Norman R; Kim RB; Schwarz UI
    Can J Psychiatry; 2017 Feb; 62(2):138-149. PubMed ID: 27681143
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.
    Cohen D; Stolk RP; Grobbee DE; Gispen-de Wied CC
    Diabetes Care; 2006 Apr; 29(4):786-91. PubMed ID: 16567816
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].
    Aguilar E; Coronas R; Caixàs A
    Med Clin (Barc); 2012 Nov; 139(12):542-6. PubMed ID: 22841467
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study.
    Balõtšev R; Haring L; Koido K; Leping V; Kriisa K; Zilmer M; Vasar V; Piir A; Lang A; Vasar E
    Early Interv Psychiatry; 2019 Feb; 13(1):101-109. PubMed ID: 28719155
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.
    Sicras-Mainar A; Blanca-Tamayo M; Rejas-Gutiérrez J; Navarro-Artieda R
    Eur Psychiatry; 2008 Mar; 23(2):100-8. PubMed ID: 17904825
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells.
    Bentsen H; Solberg DK; Refsum H; Bøhmer T
    Prostaglandins Leukot Essent Fatty Acids; 2012 Jul; 87(1):35-41. PubMed ID: 22705264
    [TBL] [Abstract][Full Text] [Related]  

  • 76. INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine.
    Koskinen S; Kampman O; Solismaa A; Lyytikäinen LP; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Mononen N; Lehtimäki T; Leinonen E
    Pharmacogenomics; 2016 Dec; 17(18):1987-1997. PubMed ID: 27885961
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.
    Guina J; Gupta A; Langleben DD; Elman I
    J Clin Psychiatry; 2016 Dec; 77(12):e1650-e1651. PubMed ID: 28086013
    [No Abstract]   [Full Text] [Related]  

  • 78. Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders.
    Scheffler F; Kilian S; Chiliza B; Asmal L; Phahladira L; du Plessis S; Kidd M; Murray RM; Di Forti M; Seedat S; Emsley R
    Schizophr Res; 2018 Sep; 199():90-95. PubMed ID: 29519756
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics.
    Leitão-Azevedo CL; Guimarães LR; de Abreu MG; Gama CS; Lobato MI; Belmonte-de-Abreu PS
    Braz J Psychiatry; 2006 Dec; 28(4):301-4. PubMed ID: 17242810
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia.
    Strassnig M; Clarke J; Mann S; Remington G; Ganguli R
    Early Interv Psychiatry; 2017 Jun; 11(3):229-236. PubMed ID: 25752319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.